8-K: CG Oncology Reports 2025 Year-End Results, Advances Bladder Cancer Pipeline

CG Oncology, Inc. announced its financial results for the year and fourth quarter ended December 31, 2025, alongside significant progress in its bladder cancer clinical programs and a strong cash position.

Summary

• Reported financial results for the fourth quarter and full year ended December 31, 2025.
• Cash, cash equivalents, and marketable securities were $742.2 million as of December 31, 2025.
• An additional $188.0 million was raised in January 2026 through an at-the-market (ATM) facility, bringing the total cash, cash equivalents, and marketable securities to approximately $903.0 million as of February 26, 2026.
• The company anticipates its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations into the first half of 2029.
• Topline data from the PIVOT-006 Phase 3 clinical trial (intermediate-risk NMIBC) is now expected in the first half of 2026, nearly a year ahead of schedule.
• First results from the CORE-008 Cohort CX Phase 2 clinical trial (combination cretostimogene with gemcitabine in high-risk NMIBC) are also expected in the first half of 2026.
• Positive clinical data was presented in December 2025 from BOND-003 Cohort P, showing HG-EFS at 3-, 6-, and 9-months of 95.7%, 84.6%, and 80.4% respectively, and from CORE-008 Cohort A, demonstrating an 88% Complete Response (CR) rate with favorable safety.
• Net loss attributable to common stockholders for the full year 2025 was $161.0 million, or ($2.08) per share, compared to $88.0 million, or ($1.41) per share, for the full year 2024.
• Research and Development (R&D) expenses increased to $116.6 million for the full year 2025 from $82.1 million in 2024.
• General and Administrative (G&A) expenses increased to $73.5 million for the full year 2025 from $33.7 million in 2024.
• The Board of Directors was strengthened with the addition of life-science executive Christina Rossi in November 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update. While financial losses increased due to R&D and G&A, the significant cash raise and expedited clinical trial timelines for key programs indicate strong operational progress and investor confidence in the long-term potential of cretostimogene.

Positives

• Strong cash position of approximately $903.0 million as of February 26, 2026, providing a significant financial runway.
• Anticipated cash runway extended into the first half of 2029, indicating financial stability for ongoing operations and clinical development.
• Expedited timeline for PIVOT-006 Phase 3 topline data, now expected in the first half of 2026, nearly a year ahead of schedule, underscoring confidence in the therapy.
• Positive clinical data presented for BOND-003 Cohort P (95.7% HG-EFS at 3 months) and CORE-008 Cohort A (88% CR), supporting cretostimogene's potential efficacy.
• Strengthened Board of Directors with the addition of Christina Rossi, bringing robust expertise in commercialization and new medicine launches.
• Advancement of cretostimogene as a potential backbone therapy for a broad range of Non-Muscle Invasive Bladder Cancer (NMIBC) patients.

Negatives

• Net loss attributable to common stockholders significantly increased to $161.0 million for the full year 2025, up from $88.0 million in 2024.
• Research and Development (R&D) expenses rose to $116.6 million for the full year 2025, compared to $82.1 million in 2024, primarily due to increased clinical trial expenses and headcount.
• General and Administrative (G&A) expenses more than doubled to $73.5 million for the full year 2025, from $33.7 million in 2024, driven by personnel, professional fees, and marketing costs.
• Net loss per share increased to ($2.08) for the full year 2025, from ($1.41) in 2024.

Risks

• Interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data becomes available.
• Potential delays in the commencement, enrollment, and completion of clinical trials, including the BOND-003 and PIVOT-006 trials.
• Capital resources may be used sooner than expected and may be insufficient to allow the company to achieve its anticipated milestones.
• Dependence on third parties in connection with manufacturing, shipping, and clinical and preclinical testing.
• Results from earlier clinical trials and preclinical studies not necessarily being predictive of future results.
• Unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval, and/or commercialization.
• Other risks described in filings with the Securities and Exchange Commission (SEC), including under the heading Risk Factors in the annual report on Form 10-K and other filings.

Future Outlook

CG Oncology anticipates its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations into the first half of 2029. The company expects topline data from the PIVOT-006 Phase 3 trial and first results from the CORE-008 Cohort CX Phase 2 trial in the first half of 2026, along with the completion of its Biologics License Application (BLA) submission in 2026 and durability data from other trials.

Management Comments

• "In the coming months, we look forward to sharing topline data from PIVOT-006, the first randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC. We believe we have the opportunity to set the new standard in intermediate-risk NMIBC." Arthur Kuan, Chairman & Chief Executive Officer.
• "I am extremely proud of our team for planning, enrolling and executing this important trial in record time." Arthur Kuan, Chairman & Chief Executive Officer.
• "With cretostimogene's unique best-in-disease profile, we remain laser-focused on advancing a comprehensive strategy designed to support an optimized product label and ensure success across additional indications—positioning cretostimogene as a potential backbone therapy for a broad range of NMIBC patients." Arthur Kuan, Chairman & Chief Executive Officer.
• "We are also looking forward to sharing results from CORE-008 Cohort CX in high-risk BCG exposed from our first trial evaluating the combination of cretostimogene with gemcitabine in the coming quarter." Arthur Kuan, Chairman & Chief Executive Officer.

Industry Context

StockSavvy.ai notes that CG Oncology is positioning cretostimogene as a potential backbone therapy for Non-Muscle Invasive Bladder Cancer (NMIBC), a significant market with unmet needs, particularly in intermediate-risk and BCG-unresponsive patient populations. The expedited timeline for PIVOT-006 data suggests strong internal confidence and could position the company as a leader in developing novel treatments for this indication, potentially disrupting existing treatment paradigms.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Potential for long-term value creation through clinical pipeline advancement and extended cash runway, but also dilution from ATM raises and increased net losses.
• Patients: Potential for new, effective treatment options for Non-Muscle Invasive Bladder Cancer (NMIBC) patients, especially with cretostimogene positioned as a potential backbone therapy.
• Employees: Increased headcount mentioned as a reason for higher G&A and R&D expenses, indicating growth and job opportunities.

Next Steps

• Share topline data from PIVOT-006 Phase 3 clinical trial in 1H26.
• Share first results from CORE-008 Cohort CX Phase 2 clinical trial in 1H26.
• Complete Biologics License Application (BLA) submission in initial indication of HR BCG-unresponsive NMIBC with CIS with or without Ta/T1 disease in 2026.
• Provide durability data from BOND-003 Cohort C, BOND-003 Cohort P, and CORE-008 Cohort A in 2026.

Key Dates

Recommendation

While CG Oncology demonstrates strong clinical progress with expedited trial timelines and positive interim data, the significant increase in net loss and operating expenses warrants caution. The substantial capital raises, while extending the cash runway, also indicate ongoing cash burn. Investors should hold, awaiting the upcoming pivotal trial data in 1H26 to assess the commercial viability and market potential of cretostimogene before making further investment decisions.

Keywords

CG Oncology, CGON, Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Cretostimogene, Oncolytic Immunotherapy, Clinical Trials, Phase 3, PIVOT-006, CORE-008, BOND-003, Biopharmaceutical, Oncology, Financial Results, Biotech